Ibrexafungerp clinical trials

How studies write it

Studies that test it under each name

Name

Ibrexafungerp: 10

Development codes

SCY-078: 10

Studies by the year they started

14 studies that test it; most in 2019 (5)

Studies that test ibrexafungerp, by start year
Year	Studies
2014	1
2015	1
2017	3
2019	5
2022	3
2023	1

Who runs them

Industry 14 · Other 0

Scynexis, Inc. (14)

Studies

Open first, then newest update. How each study uses ibrexafungerp is read from its arms, and is right about nine times in ten.

Testing it · 14

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleTerminatedPhase 3Scynexis, Inc.NCT05178862Written as SCY-078
Pharmacokinetic Study in Healthy Lactating Women Exposed to IbrexafungerpCompletedPhase 1Scynexis, Inc.NCT06954493Written as Ibrexafungerp
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentCompletedPhase 3Scynexis, Inc.NCT03059992Written as Ibrexafungerp
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisTerminatedPhase 2Scynexis, Inc.NCT03672292Written as SCY-078
Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisCompletedPhase 3Scynexis, Inc.NCT05399641Written as Ibrexafungerp
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)CompletedPhase 3Scynexis, Inc.NCT03363841Written as SCY-078
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisCompletedPhase 2Scynexis, Inc.NCT02244606Written as SCY-078
ADME Study of [14^C]-Ibrexafungerp in Healthy Male SubjectsCompletedPhase 1Scynexis, Inc.NCT05668429Written as Ibrexafungerp
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)CompletedPhase 3Scynexis, Inc.NCT04029116Written as IBREXAFUNGERP
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal CandidiasisCompletedPhase 3Scynexis, Inc.NCT03987620Written as Ibrexafungerp
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)CompletedPhase 3Scynexis, Inc.NCT03734991Written as Ibrexafungerp
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal CandidiasisCompletedPhase 2Scynexis, Inc.NCT03253094Written as SCY-078
ADME Study of [14C]-Ibrexafungerp in Healthy Male SubjectsCompletedPhase 1Scynexis, Inc.NCT04307082Written as [14C]-Ibrexafungerp
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal CandidiasisCompletedPhase 2Scynexis, Inc.NCT02679456Written as SCY-078

Codes

What other systems call ibrexafungerp · ClinicalTrials.gg INT005970

MeSH (NLM) C569338ibrexafungerpConfirmed ClinicalTrials.gov, NLM
UNII (FDA) A92JFM5XNUIBREXAFUNGERPConfirmed FDA, NLM, Wikidata
RxNorm 2560213One source FDA
Wikidata Q27273787ibrexafungerpConfirmed FDA, NLM, Wikidata
NCI Thesaurus C162185IbrexafungerpOne source FDA
DrugBank DB12471One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	C569338	ibrexafungerp	Confirmed ClinicalTrials.gov, NLM
UNII (FDA)	A92JFM5XNU	IBREXAFUNGERP	Confirmed FDA, NLM, Wikidata
RxNorm	2560213	—	One source FDA
Wikidata	Q27273787	ibrexafungerp	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C162185	Ibrexafungerp	One source FDA
DrugBank	DB12471	—	One source Wikidata

Also registered as ibrexafungerp citrate (UNII M4NU2SDX3E · RxNorm 2560215).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.